What the FDA labels say about taking them together
Aspirin, butalbital, caffeine and codeine and glipizide
Aspirin, butalbital, caffeine and codeine's FDA label of May 27, 2026 names glipizide in its drug interactions section; glipizide's label does not name aspirin, butalbital, caffeine and codeine itself but warns about its class (Barbiturates, Stimulants, NSAIDs (nonsteroidal anti-inflammatory drugs), Opioids (opioid agonists), platelet aggregation inhibitors). The aspirin, butalbital, caffeine and codeine label: “Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia.”
Check it at the source: the aspirin, butalbital, caffeine and codeine FDA label on DailyMed (effective May 27, 2026, Bryant Ranch Prepack); the glipizide FDA label on DailyMed (effective January 8, 2026, Aurobindo Pharma Limited).
What does the aspirin, butalbital, caffeine and codeine label say about glipizide?
Aspirin, butalbital, caffeine and codeine label, drug interactionsClinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Intervention: Patients should be advised to consult a physician if any signs or symptoms of hypoglycemia occur. Insulin, glimepiride, glipizide Anticonvulsants
Source: FDA drug label (BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE), ANDA075231 (Lgm Pharma), as published by Bryant Ranch Prepack, effective May 27, 2026 (SPL set 95a33c9b-79a6-47c7-8433-fc217950b88f), via openFDA; the full label on DailyMed
What does the glipizide label say about aspirin, butalbital, caffeine and codeine?
Glipizide's label does not name aspirin, butalbital, caffeine and codeine itself; it warns about its class (Barbiturates, Stimulants, NSAIDs (nonsteroidal anti-inflammatory drugs), Opioids (opioid agonists), platelet aggregation inhibitors):
Glipizide label, drug interactionsThe following are examples of medication that may increase the glucose lowering effect of glipizide extended-release tablets, increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol …
Glipizide label, drug interactionsThe following are examples of medication that may increase the glucose lowering effect of GLUCOTROL XL, increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins …
Source: FDA drug label (Glipizide), Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aspirin, butalbital, caffeine and codeine | Glipizide | |
|---|---|---|
| Labeled for | Pain | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.00 per capsule Ascomp with codeine capsule | $0.0339 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once